keyword
MENU ▼
Read by QxMD icon Read
search

Ponesimod

keyword
https://www.readbyqxmd.com/read/27638335/impact-of-demographics-organ-impairment-disease-formulation-and-food-on-the-pharmacokinetics-of-the-selective-s1p1-receptor-modulator-ponesimod-based-on-13-clinical-studies
#1
Dominik Lott, Thorsten Lehr, Jasper Dingemanse, Andreas Krause
BACKGROUND: Ponesimod is a selective, orally active sphingosine-1-phosphate receptor 1 modulator currently undergoing clinical evaluation for the treatment of multiple sclerosis (MS) in phase III clinical trials. Ponesimod dose-dependently reduces peripheral blood lymphocyte counts by blocking the egress of lymphocytes from lymphoid organs. METHODS: A population pharmacokinetic (PK) analysis was performed based on pooled data from 13 clinical studies. Interindividual variability (IIV) and the impact of key demographic variables and other covariates on ponesimod exposure were assessed quantitatively...
September 15, 2016: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/27558098/mitigation-of-initial-cardiodynamic-effects-of-the-s1p1-receptor-modulator-ponesimod-using-a-novel-up-titration-regimen
#2
Pierre-Eric Juif, Matthias Hoch, Andrea Vaclavkova, Andreas Krause, Jim Bush, Jasper Dingemanse
Ponesimod, a potent selective sphingosine-1-phosphate receptor 1 modulator, leads to a reduction in circulating total lymphocyte count and transient decreases in heart rate (HR). Based on a modeling and simulation approach, this study was conducted to investigate whether a gradual up-titration regimen may mitigate these cardiodynamic effects. In this double-blind, placebo-controlled, randomized, two-way cross-over study, 32 healthy subjects (15 males) received placebo on Day 1 followed by multiple-dose administration of either ponesimod or placebo (ratio 3:1)...
August 25, 2016: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27108115/population-pharmacokinetics-of-ponesimod-and-its-primary-metabolites-in-healthy-and-organ-impaired-subjects
#3
Dominik Lott, Andreas Krause, Jasper Dingemanse, Thorsten Lehr
Ponesimod, a selective, orally active S1P1 receptor modulator, reduces total blood lymphocyte counts by blocking the egress of lymphocytes from lymphoid organs. It is currently in clinical development for the treatment of relapsing-remitting multiple sclerosis. Ponesimod has two primary metabolites, M12 and M13, that circulate in human plasma. The work presented in this paper predicts and quantifies the accumulation of ponesimod and both metabolites in healthy and organ-impaired subjects. Based on clinical data including studies in renally and hepatically impaired subjects, a population pharmacokinetic (PK) model was developed to characterize the PK of ponesimod and its primary metabolites and to qualify and quantify the influence of organ impairment on the concentration-time profiles of these compounds...
June 30, 2016: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/26923915/novel-oral-therapies-for-psoriasis-and-psoriatic-arthritis
#4
Zenas Z N Yiu, Richard B Warren
Several classes of new oral therapy are in use or in development for the treatment of psoriasis. Despite the high efficacy of biologics, new oral therapies remain important as patients generally prefer this mode of administration and they offer an alternative risk-benefit profile. In this review, we discuss the novel modes of action of these drugs, including modulation of cellular pathways involving diverse targets such as Janus kinase, phosphodiesterase 4, sphingosine 1-phosphate, A3 adenosine receptor and rho-associated kinase 2...
June 2016: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/26883438/absolute-bioavailability-of-ponesimod-a-selective-s1p1-receptor-modulator-in-healthy-male-subjects
#5
Margaux Boehler, Pierre-Eric Juif, Matthias Hoch, Jasper Dingemanse
BACKGROUND AND OBJECTIVES: The pharmacokinetic profile of ponesimod, a sphingosine-1-phosphate receptor 1 modulator, is characterized by a rapid absorption [time to maximum concentration (t max) of 2-4 h] and a terminal half-life (t ½) of 32 h after single-dose administration. The aim of this study was to assess additional pharmacokinetic parameters [absolute bioavailability, total clearance (CL), and volume of distribution (V ss)] in healthy male subjects. METHODS: After ensuring in a pilot phase the full pharmacokinetic profile, safety, and tolerability of a 5-mg intravenous infusion of ponesimod over 3 h (treatment A), the study proceeded to the randomized, two-way crossover, single-dose (treatment A; treatment B: 10 mg oral) main phase...
February 16, 2016: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/26786937/the-role-of-epidermal-sphingolipids-in-dermatologic-diseases
#6
Sonia Borodzicz, Lidia Rudnicka, Dagmara Mirowska-Guzel, Agnieszka Cudnoch-Jedrzejewska
Sphingolipids, a group of lipids containing the sphingoid base, have both structural and biological functions in human epidermis. Ceramides, as a part of extracellular lipids in the stratum corneum, are important elements of the skin barrier and are involved in the prevention of transepidermal water loss. In addition, ceramides regulate such processes as proliferation, differentiation and apoptosis of keratinocytes. Another important sphingolipid, sphingosine-1-phosphate (S1P), inhibits proliferation and induces differentiation of keratinocytes...
2016: Lipids in Health and Disease
https://www.readbyqxmd.com/read/26770667/ponesimod-a-selective-s1p1-receptor-modulator-a-potential-treatment-for-multiple-sclerosis-and-other-immune-mediated-diseases
#7
REVIEW
Daniele D'Ambrosio, Mark S Freedman, Joerg Prinz
The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P1R, in regulation of lymphocyte trafficking in multiple sclerosis. Modulation of S1P3R, initially thought to cause some of fingolimod's side effects, prompted the search for novel compounds with high selectivity for S1P1R. Ponesimod is an orally active, selective S1P1R modulator that causes dose-dependent sequestration of lymphocytes in lymphoid organs...
January 2016: Therapeutic Advances in Chronic Disease
https://www.readbyqxmd.com/read/26702336/the-latest-innovations-in-the-drug-pipeline-for-multiple-sclerosis
#8
Lea Radick, Stanton R Mehr
Several new medications are being investigated in late-phase studies for the treatment of patients with relapsing or progressive multiple sclerosis (MS). These agents represent a variety of mechanisms of action and provide not only lower relapse rates but also improvement in disabilities. The majority of investigational trials involve selective sphingosine-1-phosphate receptor 1 immunomodulators, such as laquinimod, ozanimod, ponesimod, and siponimod, in an effort to build on the success of fingolimod. Ocrelizumab is a CD20-positive B-cell-targeting monoclonal antibody with a promising new mechanism of action...
November 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26525450/effect-of-hepatic-or-renal-impairment-on-the-pharmacokinetics-safety-and-tolerability-of-ponesimod-a-selective-s1p1-receptor-modulator
#9
Nicolas Guérard, Christian Zwingelstein, Matthias Hoch, Jasper Dingemanse
Ponesimod, a selective S1P1 receptor modulator, is a potential therapeutic agent for autoimmune disorders. The impact of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of ponesimod and its inactive metabolites, ACT-204426 and ACT-338375, was evaluated. Two separate single-centre, open-label studies with 32 (hepatic study) and 24 (renal study) male and female individuals were conducted. Hepatic impairment was based on the Child-Pugh classification, and renal impairment was determined by creatinine clearance using the Cockcroft-Gault equation...
May 2016: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/26239599/sphingosine-1-phosphate-receptor-modulators-in-multiple-sclerosis
#10
REVIEW
Adnan M Subei, Jeffrey A Cohen
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor's function and sequester lymphocytes in lymph nodes. Fingolimod was the first S1P agent approved in the USA in 2010 for relapsing MS after two phase III trials (FREEDOMS and TRANSFORMS) demonstrated potent efficacy, and good safety and tolerability...
July 2015: CNS Drugs
https://www.readbyqxmd.com/read/25939333/biocomparison-of-three-formulations-of-the-s1p1-receptor-modulator-ponesimod-in-healthy-subjects
#11
RANDOMIZED CONTROLLED TRIAL
Pierre-Eric Juif, Matthias Hoch, Daniele D'Ambrosio, Jasper Dingemanse
BACKGROUND: Ponesimod is a potent selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, which leads to a reduction in circulating lymphocytes, reflecting their sequestration within lymphoid organs. Modulation of the S1P1 receptor has been previously described to be an effective treatment of autoimmune diseases (e.g., multiple sclerosis). OBJECTIVES: The aim of this study was to compare the relative bioavailability of two polymorphic forms of ponesimod in capsules (Form A versus Form C; Study 1) and the relative bioavailability of a capsule formulation and a tablet formulation (both polymorphic Form C; Study 2)...
June 2015: Drugs in R&D
https://www.readbyqxmd.com/read/25612299/three-different-up-titration-regimens-of-ponesimod-an-s1p1-receptor-modulator-in-healthy-subjects
#12
RANDOMIZED CONTROLLED TRIAL
Michael W Scherz, Patrick Brossard, Daniele D'Ambrosio, Murat Ipek, Jasper Dingemanse
Ponesimod is a selective S1P1 receptor modulator, and induces dose-dependent reduction of circulating lymphocytes upon oral dosing. Previous studies showed that single doses up to 75 mg or multiple doses up to 40 mg once daily are well tolerated, and heart rate (HR) reduction and atrio-ventricular conduction delays upon treatment initiation are reduced by gradual up-titration to the maintenance dose. This single-center, open-label, randomized, multiple-dose, 3-treatment, 3-way crossover study compared the tolerability, safety, pharmacokinetics, cardiodynamics, and effects on lymphocytes of 3 different up-titration regimens of ponesimod in healthy male and female subjects...
June 2015: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/25580263/s1p-signaling-new-therapies-and-opportunities
#13
REVIEW
Pedro J Gonzalez-Cabrera, Steve Brown, Sean M Studer, Hugh Rosen
Development of sphingosine-1-phosphate receptor 1 (S1P1) modulators to dampen inflammation and its sequelae is becoming increasingly promising for treating medical conditions characterized by significant immunopathology. As shown by the non-selective S1P receptor modulator FTY720 (fingolimod [Gilenya(®)]) in the treatment of relapsing-remitting multiple sclerosis (MS), the ability to use S1P1 modulation to precisely block immune cell traffic-immunomodulation-while maintaining immunosurveillance, has opened therapeutic opportunities in various other immune-derived chronic pathologies, including inflammatory bowel disease (IBD), lupus, psoriasis, as well as, potentially, in early acute viral respiratory infection...
2014: F1000Prime Reports
https://www.readbyqxmd.com/read/25539756/-what-s-new-in-dermatological-therapy
#14
REVIEW
L Meunier
This non-exhaustive review focuses on publications that have been the subject of randomized controlled trials. It will also include results from research that may lead to new therapeutic perspectives. The selected articles were published between October 2013 and September 2014. The vast majority of them were dedicated to the treatment of psoriasis (anti-TNF, ustekinumab, antibodies against IL-17 or its receptors, anti-IL-23, anti-CD6 and ponesimod). Selected papers will also address the following diseases: atopic dermatitis, urticaria, acne, bullous diseases, alopecia areata, skin infections, acne rosacea and leg ulcers...
December 2014: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/25519470/differential-effects-of-ponesimod-a-selective-s1p1-receptor-modulator-on-blood-circulating-human-t-cell-subpopulations
#15
RANDOMIZED CONTROLLED TRIAL
Daniele D'Ambrosio, Jörg Steinmann, Patrick Brossard, Jasper Dingemanse
Ponesimod, a novel selective sphingosine-1-phosphate 1 receptor modulator in the development for the treatment of autoimmune diseases, dose-dependently reduced lymphocyte counts in peripheral blood of healthy subjects. It rapidly and transiently reduced the number of circulating T and B cells, but not natural killer cells. T lymphocyte subsets exhibited differential sensitivities with a maximum decrease from baseline ranging from 67% to 89% following high doses. Naïve T cells were more sensitive than memory T cells...
February 2015: Immunopharmacology and Immunotoxicology
https://www.readbyqxmd.com/read/25402365/effects-of-ethnicity-and-sex-on-the-pharmacokinetics-and-pharmacodynamics-of-the-selective-sphingosine-1-phosphate-receptor-1-modulator-ponesimod-a-clinical-study-in-japanese-and-caucasian-subjects
#16
Maribel Reyes, Matthias Hoch, Patrick Brossard, Jasper Dingemanse
The aim of this study was to evaluate the relative pharmacokinetic (PK) and pharmacodynamic (PD) properties of a single dose of ponesimod, an oral and selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, in Japanese and Caucasian healthy subjects and explore the effects of sex on PK. Subjects received a single 40-mg dose of ponesimod in a single-centre, open-label, parallel-group study design. Ten Japanese and 10 Caucasian healthy subjects (age: 22-45 years, 1:1 sex ratio) participated in the study and were matched for body weight (±10%)...
2014: Pharmacology
https://www.readbyqxmd.com/read/25287214/effect-of-ponesimod-a-selective-s1p1-receptor-modulator-on-the-qt-interval-in-healthy-individuals
#17
RANDOMIZED CONTROLLED TRIAL
Matthias Hoch, Borje Darpo, Patrick Brossard, Meijian Zhou, Randall Stoltz, Jasper Dingemanse
Ponesimod is an orally active selective sphingosine-1-phosphate receptor 1 modulator under investigation for the treatment of multiple sclerosis. This was a single-centre, double-blind, randomized, placebo- and positive-controlled parallel-group study investigating the effects of ponesimod on the QTc interval in healthy individuals. A nested cross-over comparison between moxifloxacin and placebo was included in the combined moxifloxacin/placebo treatment group. Subjects in group A received multiple doses of 10-100 mg ponesimod according to an uptitration regimen on days 2-23 and moxifloxacin-matching placebo on days 1 and 24...
May 2015: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/25188442/mass-balance-pharmacokinetics-and-metabolism-of-the-selective-s1p1-receptor-modulator-ponesimod-in-humans
#18
Maribel Reyes, Matthias Hoch, Patrick Brossard, Winfried Wagner-Redeker, Tommaso Miraval, Jasper Dingemanse
1. Ponesimod [(R)-5-[3-chloro-4-(-2,3-dihydroxy-propoxy)-benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one] is an orally administered, selective S1P1 receptor modulator that blocks the egress of lymphocytes from lymphoid organs and reduces the availability of circulating effector T/B-cells. 2. The mass balance, pharmacokinetics and metabolism of 40 mg (14)C-ponesimod were investigated in six healthy male subjects. The total radioactivity in whole blood, plasma, urine, faeces and expired CO2 was determined by liquid scintillation counting...
February 2015: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/25127208/oral-ponesimod-in-patients-with-chronic-plaque-psoriasis-a-randomised-double-blind-placebo-controlled-phase-2-trial
#19
RANDOMIZED CONTROLLED TRIAL
Andrea Vaclavkova, Sergio Chimenti, Petr Arenberger, Peter Holló, Paul-Gunther Sator, Michel Burcklen, Mylène Stefani, Daniele D'Ambrosio
BACKGROUND: We assessed the efficacy, safety, and tolerability of ponesimod, an oral, selective, reversible modulator of sphingosine 1-phosphate receptor 1, in patients with moderate to severe chronic plaque psoriasis. METHODS: Between Sept 22, 2010, and Oct 24, 2012, patients with psoriasis area and severity index (PASI) scores higher than 10 were enrolled into this multicentre double-blind, phase 2 study. They received 20 mg or 40 mg ponesimod or placebo once daily for 16 weeks...
December 6, 2014: Lancet
https://www.readbyqxmd.com/read/25127207/ponesimod-a-future-oral-therapy-for-psoriasis
#20
COMMENT
Caitriona Ryan, Alan Menter
No abstract text is available yet for this article.
December 6, 2014: Lancet
keyword
keyword
102005
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"